Comparison of the Effects of Different Potent Adjuvants on Enhancing the Immunogenicity and Cross-protection by Influenza Virus Vaccination in Young and Aged Mice

Overview

Journal Antiviral Res

Publisher Elsevier

Date 2021 Dec 21

PMID 34933043

Citations 5

Authors

Noopur Bhatnagar

Ki-Hye Kim

Jeeva Subbiah

Bo Ryoung Park

Eun-Ju Ko

Baik-Lin Seong

Sang-Moo Kang

Affiliations

Soon will be listed here.

Abstract

Vaccination against influenza viruses suffers from low efficacy in conferring homologous and cross-protection, particularly in older adults. Here, we compared the effects of three different adjuvant types (QS-21+MPL, CpG+MPL and bacterial cell wall CWS) on enhancing the immunogenicity and homologous and heterosubtypic protection of influenza vaccination in young adult and aged mouse models. A combination of saponin QS-21 and monophosphoryl lipid A (QS-21+MPL) was most effective in inducing T helper type 1 (Th1) T cell and cross-reactive IgG as well as hemagglutination inhibiting antibody responses to influenza vaccination. Both combination adjuvants (QS-21+MPL and CpG+MPL) exhibited high potency by preventing weight loss and reducing viral loads and enhanced homologous and cross-protection by influenza vaccination in adult and aged mouse models. Bacillus Calmette-Guerin cell-wall skeleton (CWS) displayed substantial adjuvant effects on immune responses to influenza vaccination but lower adjuvant efficacy in inducing Th1 IgG responses, cross-protection in adult mice, and in conferring homologous protection in aged mice. This study has significance in comparing the effects of potent adjuvants on enhancing humoral and cellular immune responses to influenza virus vaccination, inducing homologous and cross-protection in adult and aged populations.

Citing Articles

Influenza 5xM2e mRNA lipid nanoparticle vaccine confers broad immunity and significantly enhances the efficacy of inactivated split vaccination when coadministered.

Grovenstein P, Bhatnagar N, Kim K, Pal S, Le C, Raha J J Immunol. 2025; 214(1):104-114.

PMID: 40073270 PMC: 11844137. DOI: 10.1093/jimmun/vkae013.

Development of semisynthetic saponin immunostimulants.

Bai D, Kim H, Wang P Med Chem Res. 2024; 33(8):1292-1306.

PMID: 39132259 PMC: 11315725. DOI: 10.1007/s00044-024-03227-x.

Supplementation of seasonal vaccine with multi-subtype neuraminidase and M2 ectodomain virus-like particle improves protection against homologous and heterologous influenza viruses in aged mice.

Raha J, Kim K, Bhatnagar N, Liu R, Le C, Park B Antiviral Res. 2024; 225:105877.

PMID: 38561077 PMC: 11023748. DOI: 10.1016/j.antiviral.2024.105877.

Heterologous Prime-Boost Vaccination with Inactivated Influenza Viruses Induces More Effective Cross-Protection than Homologous Repeat Vaccination.

Bhatnagar N, Kim K, Subbiah J, Muhammad-Worsham S, Park B, Liu R Vaccines (Basel). 2023; 11(7).

PMID: 37515025 PMC: 10386405. DOI: 10.3390/vaccines11071209.

Adjuvant Effects of a New Saponin Analog VSA-1 on Enhancing Homologous and Heterosubtypic Protection by Influenza Virus Vaccination.

Bhatnagar N, Kim K, Subbiah J, Park B, Wang P, Gill H Vaccines (Basel). 2022; 10(9).

PMID: 36146461 PMC: 9501088. DOI: 10.3390/vaccines10091383.

References

Oishi K, Koles N, Guelde G, Pollack M . Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity. J Infect Dis. 1992; 165(1):34-45. DOI: 10.1093/infdis/165.1.34. View

Lee Y, Ko E, Lee Y, Kim K, Kim M, Lee Y . Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses. PLoS One. 2018; 13(1):e0190868. PMC: 5764335. DOI: 10.1371/journal.pone.0190868. View

Coccia M, Collignon C, Herve C, Chalon A, Welsby I, Detienne S . Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity. NPJ Vaccines. 2017; 2:25. PMC: 5627273. DOI: 10.1038/s41541-017-0027-3. View

Chen Z, Yoshikawa T, Kadowaki S, Hagiwara Y, Matsuo K, Asanuma H . Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. J Gen Virol. 1999; 80 ( Pt 10):2559-2564. DOI: 10.1099/0022-1317-80-10-2559. View

Stevens T, Bossie A, Sanders V, Fernandez-Botran R, Coffman R, Mosmann T . Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature. 1988; 334(6179):255-8. DOI: 10.1038/334255a0. View

Escobar L, Molina-Cruz A, Barillas-Mury C . BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci U S A. 2020; 117(30):17720-17726. PMC: 7395502. DOI: 10.1073/pnas.2008410117. View

Ko E, Lee Y, Lee Y, Kim Y, Kim K, Kang S . MPL and CpG combination adjuvants promote homologous and heterosubtypic cross protection of inactivated split influenza virus vaccine. Antiviral Res. 2018; 156:107-115. PMC: 6590071. DOI: 10.1016/j.antiviral.2018.06.004. View

. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014; 11(7):e1001685. PMC: 4114488. DOI: 10.1371/journal.pmed.1001685. View

Kim K, Lee Y, Park Y, Ko E, Jung Y, Kim Y . BCG Cell Wall Skeleton As a Vaccine Adjuvant Protects Both Infant and Old-Aged Mice from Influenza Virus Infection. Biomedicines. 2021; 9(5). PMC: 8148143. DOI: 10.3390/biomedicines9050516. View

10.

Van Der Meeren O, Hatherill M, Nduba V, Wilkinson R, Muyoyeta M, van Brakel E . Phase 2b Controlled Trial of M72/AS01 Vaccine to Prevent Tuberculosis. N Engl J Med. 2018; 379(17):1621-1634. PMC: 6151253. DOI: 10.1056/NEJMoa1803484. View

11.

Cunningham A, Lal H, Kovac M, Chlibek R, Hwang S, Diez-Domingo J . Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016; 375(11):1019-32. DOI: 10.1056/NEJMoa1603800. View

12.

Misplon J, Lo C, Gabbard J, Tompkins S, Epstein S . Genetic control of immune responses to influenza A matrix 2 protein (M2). Vaccine. 2010; 28(36):5817-27. DOI: 10.1016/j.vaccine.2010.06.069. View

13.

Dendouga N, Fochesato M, Lockman L, Mossman S, Giannini S . Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine. 2012; 30(20):3126-35. DOI: 10.1016/j.vaccine.2012.01.088. View

14.

Kipps T, Parham P, Punt J, Herzenberg L . Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J Exp Med. 1985; 161(1):1-17. PMC: 2187540. DOI: 10.1084/jem.161.1.1. View

15.

Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, Hayashi A . Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: involvement of toll-like receptors. Infect Immun. 2000; 68(12):6883-90. PMC: 97794. DOI: 10.1128/IAI.68.12.6883-6890.2000. View

16.

Viboud C, Miller M, Olson D, Osterholm M, Simonsen L . Preliminary Estimates of Mortality and Years of Life Lost Associated with the 2009 A/H1N1 Pandemic in the US and Comparison with Past Influenza Seasons. PLoS Curr. 2010; 2:RRN1153. PMC: 2843747. DOI: 10.1371/currents.rrn1153. View

17.

Young B, Sadarangani S, Leo Y . The avian influenza vaccine Emerflu. Why did it fail?. Expert Rev Vaccines. 2015; 14(8):1125-34. DOI: 10.1586/14760584.2015.1059760. View

18.

Kodama K, Higashiyama M, Takami K, Oda K, Okami J, Maeda J . Innate immune therapy with a Bacillus Calmette-Guérin cell wall skeleton after radical surgery for non-small cell lung cancer: a case-control study. Surg Today. 2009; 39(3):194-200. DOI: 10.1007/s00595-008-3826-3. View

19.

Iuliano A, Roguski K, Chang H, Muscatello D, Palekar R, Tempia S . Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2017; 391(10127):1285-1300. PMC: 5935243. DOI: 10.1016/S0140-6736(17)33293-2. View

20.

Kim K, Lee Y, Park S, Jung Y, Lee Y, Ko E . Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus. Virology. 2019; 535:179-188. PMC: 6946909. DOI: 10.1016/j.virol.2019.07.008. View